{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:08:53Z","timestamp":1789006133088,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dalian Medical Science Research Program","award":["2023DF016"],"award-info":[{"award-number":["2023DF016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04434-8","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:45:10Z","timestamp":1760697910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiahui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-1952","authenticated-orcid":false,"given":"Xiaofei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-296X","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"4434_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","volume":"20","author":"VL Feigin","year":"2021","unstructured":"Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20:795\u2013820.","journal-title":"Lancet Neurol"},{"key":"4434_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.12.36","volume":"8","author":"P Liu","year":"2020","unstructured":"Liu P, Liu S, Feng N, Wang Y, Gao Y, Wu J. Association between neurological deterioration and outcomes in patients with stroke. Ann Transl Med. 2020;8:4.","journal-title":"Ann Transl Med"},{"key":"4434_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","volume":"86","author":"P Seners","year":"2015","unstructured":"Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24\u00a0h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86:87\u201394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4434_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1210","volume":"9","author":"X Hou","year":"2019","unstructured":"Hou X, Chen W, Xu H, Zhu Z, Xu Y, Chen H. The rate of early neurological deterioration occurring after thrombolytic therapy: a meta-analysis. Brain Behav. 2019;9:e01210.","journal-title":"Brain Behav"},{"key":"4434_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/neurintsurg-2022-018844","volume":"15","author":"R Bhole","year":"2023","unstructured":"Bhole R, Nouer SS, Tolley EA, Turk A, Siddiqui AH, Alexandrov AV, Art, et al. Predictors of early neurologic deterioration (END) following stroke thrombectomy. J Neurointerv Surg. 2023;15:584\u2013588.","journal-title":"J Neurointerv Surg"},{"key":"4434_CR6","first-page":"1","volume":"24","author":"J Wang","year":"2025","unstructured":"Wang J, Zhao M, Qiao Y, Li S, Ji X, Zhao W. Neurological deterioration after acute ischemic stroke: a common phenomenon with important implications. Cerebrovasc Dis. 2025;24:1\u201316.","journal-title":"Cerebrovasc Dis"},{"key":"4434_CR7","doi-asserted-by":"publisher","first-page":"175628642211477","DOI":"10.1177\/17562864221147743","volume":"16","author":"H Liu","year":"2023","unstructured":"Liu H, Liu K, Zhang K, Zong C, Yang H, Li Y, et al. Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study. Ther Adv Neurol Disord. 2023;16:17562864221147743.","journal-title":"Ther Adv Neurol Disord"},{"key":"4434_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12883-023-03128-3","volume":"23","author":"D Jin","year":"2023","unstructured":"Jin D, Yang J, Zhu H, Wu Y, Liu H, Wang Q, et al. Risk factors for early neurologic deterioration in single small subcortical infarction without carrier artery stenosis: predictors at the early stage. BMC Neurol. 2023;23:83.","journal-title":"BMC Neurol"},{"key":"4434_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","volume":"389","author":"GJ Hankey","year":"2017","unstructured":"Hankey GJ. Stroke. Lancet. 2017;389:641\u2013 654.","journal-title":"Lancet"},{"key":"4434_CR10","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2019;50:e344-e418.","journal-title":"Stroke"},{"key":"4434_CR11","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1001\/jama.2023.7827","volume":"329","author":"HS Chen","year":"2023","unstructured":"Chen HS, Cui Y, Zhou ZH, Zhang H, Wang LX, Wang WZ, et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial. JAMA. 2023;329:2135\u20132144.","journal-title":"JAMA"},{"key":"4434_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamaneurol.2024.0146","volume":"81","author":"HS Chen","year":"2024","unstructured":"Chen HS, Cui Y, Wang XH, Ma YT, Han J, Duan YJ, et al. Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke: the ATAMIS randomized clinical trial. JAMA Neurol. 2024;81:450\u2013460.","journal-title":"JAMA Neurol"},{"key":"4434_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamaneurol.2023.5093","volume":"81","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhong W, Xue R, Jin H, Gong X, Huang Y, et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration: A randomized clinical trial. JAMA Neurol. 2024;81:118\u2013125.","journal-title":"JAMA Neurol"},{"key":"4434_CR14","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1007\/s00415-018-8998-1","volume":"265","author":"X Yi","year":"2018","unstructured":"Yi X, Zhou Q, Wang C, Lin J, Chai Z. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. J Neurol. 2018;265:2396\u20132403.","journal-title":"J Neurol"},{"key":"4434_CR15","doi-asserted-by":"publisher","first-page":"10221","DOI":"10.3390\/ijms231810221","volume":"23","author":"S Ilut","year":"2022","unstructured":"Ilut S, Pirlog BO, Pirlog R, Nutu A, Vacaras V, Armean SM. Recent advances on the roles of PCSK-9 inhibitors in the management of acute ischemic stroke patients. Int J Mol Sci. 2022;23:10221.","journal-title":"Int J Mol Sci"},{"key":"4434_CR16","doi-asserted-by":"publisher","first-page":"1148486","DOI":"10.3389\/fcvm.2023.1148486","volume":"10","author":"M Ma","year":"2023","unstructured":"Ma M, Hou C, Liu J. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: focus on immune regulation. Front Cardiovasc Med. 2023;10:1148486.","journal-title":"Front Cardiovasc Med"},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","volume":"20","author":"AD Karagiannis","year":"2018","unstructured":"Karagiannis AD, Liu M, Toth PP, Zhao S, Agrawal DK, Libby P, et al. Pleiotropic Anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20:20.","journal-title":"Curr Atheroscler Rep"},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-024-01145-5","volume":"39","author":"W Tian","year":"2025","unstructured":"Tian W, Cao H, Li X, Gong X, Yu X, Li D, et al. Adjunctive PCSK9 inhibitor Evolocumab in the prevention of early neurological deterioration in Non-cardiogenic acute ischemic stroke: A multicenter, prospective, randomized, Open-Label, clinical trial. CNS Drugs. 2025;39:197\u2013208.","journal-title":"CNS Drugs"},{"key":"4434_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","volume":"24","author":"HP Adams Jr.","year":"1993","unstructured":"Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35\u201341.","journal-title":"Stroke"},{"key":"4434_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13849","volume":"52","author":"M Nath","year":"2022","unstructured":"Nath M, Swarnkar P, Sharma R, Kumar A, Misra S, Kumar P. Association of modifiable risk factors with ischaemic stroke subtypes in Asian versus Caucasian populations: a systematic review and meta-analysis. Eur J Clin Invest. 2022;52:e13849.","journal-title":"Eur J Clin Invest"},{"key":"4434_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jnnp-2012-303638","volume":"84","author":"E Cuadrado-Godia","year":"2013","unstructured":"Cuadrado-Godia E, Jimena S, Ois A, Rodr\u00edguez-Campello A, Giralt-Steinhauer E, Soriano-Tarraga C, et al. Factors associated with early outcome in patients with large-vessel carotid strokes. J Neurol Neurosurg Psychiatry. 2013;84:305\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4434_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5853\/jos.2016.00073","volume":"18","author":"JE Siegler","year":"2016","unstructured":"Siegler JE, Samai A, Semmes E, Martin-Schild S. Early neurologic deterioration after stroke depends on vascular territory and stroke etiology. J Stroke. 2016;18:203\u201310.","journal-title":"J Stroke"},{"key":"4434_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105892","volume":"195","author":"SM Sung","year":"2020","unstructured":"Sung SM, Kang YJ, Cho HJ, Kim NR, Lee SM, Choi BK, et al. Prediction of early neurological deterioration in acute minor ischemic stroke by machine learning algorithms. Clin Neurol Neurosurg. 2020;195:105892.","journal-title":"Clin Neurol Neurosurg"},{"key":"4434_CR24","doi-asserted-by":"publisher","first-page":"e1437","DOI":"10.1212\/WNL.0000000000012661","volume":"97","author":"J Vynckier","year":"2021","unstructured":"Vynckier J, Maamari B, Grunder L, Goeldlin MB, Meinel TR, Kaesmacher J, et al. Early neurologic deterioration in lacunar stroke: clinical and imaging predictors and association with long-term outcome. Neurology. 2021;97:e1437-e1446.","journal-title":"Neurology"},{"key":"4434_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/STROKEAHA.114.007466","volume":"46","author":"HG Jeong","year":"2015","unstructured":"Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ. Neuroimaging markers for early neurologic deterioration in single small subcortical infarction. Stroke. 2015;46:687\u201391.","journal-title":"Stroke"},{"key":"4434_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107120","volume":"213","author":"C Sales","year":"2022","unstructured":"Sales C, Calma AD. Stroke warning syndrome. Clin Neurol Neurosurg. 2022;213:107120.","journal-title":"Clin Neurol Neurosurg"},{"key":"4434_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaneurol.2016.5815","volume":"74","author":"EM Arsava","year":"2017","unstructured":"Arsava EM, Helenius J, Avery R, Sorgun MH, Kim GM, Pontes-Neto OM, et al. Assessment of the predictive validity of etiologic stroke classification. JAMA Neurol. 2017;74:419\u2013426.","journal-title":"JAMA Neurol"},{"key":"4434_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105459","volume":"30","author":"X Xie","year":"2021","unstructured":"Xie X, Xiao J, Wang Y, Pan L, Ma J, Deng L, et al. Predictive model of early neurological deterioration in patients with acute ischemic stroke: a retrospective cohort study. J Stroke Cerebrovasc Dis. 2021;30:105459.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"4434_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107673","volume":"228","author":"H Li","year":"2023","unstructured":"Li H, Zhang JT, Zheng Y, Zhang DD, Cui XY, Zhao X, et al. Risk factors and prognosis of early neurological deterioration in patients with posterior circulation cerebral infarction. Clin Neurol Neurosurg. 2023;228:107673.","journal-title":"Clin Neurol Neurosurg"},{"key":"4434_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/0115672026287986240104074006","volume":"21","author":"Y Xie","year":"2024","unstructured":"Xie Y, Li S, Liu L, Tang S, Liu Y, Tan S, et al. Risk factors and prognosis of early neurological deterioration after bridging therapy. Curr Neurovasc Res. 2024;21:25\u201331.","journal-title":"Curr Neurovasc Res"},{"key":"4434_CR31","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452\u20132462.","journal-title":"J Am Coll Cardiol"},{"key":"4434_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15:1308\u20131321.","journal-title":"JACC Cardiovasc Imaging"},{"key":"4434_CR33","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.STR.25.11.2220","volume":"25","author":"P Lyden","year":"1994","unstructured":"Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH stroke scale using video training. NINDS TPA stroke study group. Stroke. 1994;25:2220\u20136.","journal-title":"Stroke"},{"key":"4434_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604\u20137.","journal-title":"Stroke"},{"key":"4434_CR35","doi-asserted-by":"publisher","first-page":"e0221597","DOI":"10.1371\/journal.pone.0221597","volume":"14","author":"KW Nam","year":"2019","unstructured":"Nam KW, Kim TJ, Lee JS, Park SH, Jeong HB, Yoon BW, et al. Neutrophil-to-lymphocyte ratio predicts early worsening in stroke due to large vessel disease. PLoS ONE. 2019;14:e0221597.","journal-title":"PLoS ONE"},{"key":"4434_CR36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u20131722.","journal-title":"N Engl J Med"},{"key":"4434_CR37","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in Statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373\u20132384.","journal-title":"JAMA"},{"key":"4434_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ehjci\/jeab034","volume":"23","author":"H Ota","year":"2022","unstructured":"Ota H, Omori H, Kawasaki M, Hirakawa A, Matsuo H. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. Eur Heart J Cardiovasc Imaging. 2022;23:217\u2013228.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4434_CR39","doi-asserted-by":"publisher","first-page":"1127534","DOI":"10.3389\/fnagi.2023.1127534","volume":"15","author":"L Wu","year":"2023","unstructured":"Wu L, Kong Q, Huang H, Xu S, Qu W, Zhang P, et al. Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: a high-resolution MRI study. Front Aging Neurosci. 2023;15:1127534.","journal-title":"Front Aging Neurosci"},{"key":"4434_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/17474930241270447","volume":"19","author":"X Hu","year":"2024","unstructured":"Hu X, Zhang Z, Liu C, Li M, Liu Y, Cheng A, et al. PCSK9 inhibitor with Statin therapy for intracranial artery stenosis (PISTIAS): rationale and design of a multicenter randomized controlled trial. Int J Stroke. 2024;19:1071\u20131076.","journal-title":"Int J Stroke"},{"key":"4434_CR41","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/STROKEAHA.122.039005","volume":"53","author":"J Boltze","year":"2022","unstructured":"Boltze J, Perez-Pinzon MA. Focused update on stroke neuroimmunology: current progress in preclinical and clinical research and recent mechanistic insight. Stroke. 2022;53:1432\u20131437.","journal-title":"Stroke"},{"key":"4434_CR42","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/01.STR.31.10.2325","volume":"31","author":"N Vila","year":"2000","unstructured":"Vila N, Castillo J, D\u00e1valos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325\u20139.","journal-title":"Stroke"},{"key":"4434_CR43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/17520363.2024.2389038","volume":"18","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Fan T. IL-6 and stroke recurrence in ischemic stroke. Biomark Med. 2024;18:739\u2013747.","journal-title":"Biomark Med"},{"key":"4434_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14648","volume":"30","author":"L Yi","year":"2024","unstructured":"Yi L, Li ZX, Jiang YY, Jiang Y, Meng X, Li H, et al. Inflammatory marker profiles and in-hospital neurological deterioration in patients with acute minor ischemic stroke. CNS Neurosci Ther. 2024;30:e14648.","journal-title":"CNS Neurosci Ther"},{"key":"4434_CR45","doi-asserted-by":"publisher","first-page":"939791","DOI":"10.3389\/fcvm.2022.939791","volume":"9","author":"Z Ou","year":"2022","unstructured":"Ou Z, Yu Z, Liang B, Zhao L, Li J, Pang X, et al. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients. Front Cardiovasc Med. 2022;9:939791.","journal-title":"Front Cardiovasc Med"},{"key":"4434_CR46","doi-asserted-by":"publisher","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","volume":"378","author":"R Marfella","year":"2023","unstructured":"Marfella R, Prattichizzo F, Sardu C, Paolisso P, D\u2019Onofrio N, Scisciola L, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378:117180.","journal-title":"Atherosclerosis"},{"key":"4434_CR47","doi-asserted-by":"publisher","first-page":"111195","DOI":"10.1016\/j.intimp.2023.111195","volume":"126","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Zhu T, Li G, Xu L, Zhang Y. PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB\/CD44 pathway. Int Immunopharmacol. 2024;126:111195.","journal-title":"Int Immunopharmacol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04434-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:03:39Z","timestamp":1760699019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04434-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04434-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University. Every patient or their legal representatives provided written informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"431"}}